Shire PLC (SHPG) Rating Reiterated by Cantor Fitzgerald
Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday. They presently have a $222.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 40.10% from the company’s current price.
Several other brokerages have also recently issued reports on SHPG. Royal Bank Of Canada set a $221.00 target price on shares of Shire PLC and gave the stock a “buy” rating in a report on Thursday, May 18th. HSBC Holdings plc cut shares of Shire PLC from a “hold” rating to a “reduce” rating in a report on Friday, May 19th. Sanford C. Bernstein cut shares of Shire PLC from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $209.22 to $161.09 in a report on Thursday, May 25th. BidaskClub upgraded shares of Shire PLC from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. Finally, ValuEngine cut shares of Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and fourteen have assigned a buy rating to the company’s stock. Shire PLC currently has a consensus rating of “Buy” and an average target price of $220.08.
Shares of Shire PLC (NASDAQ:SHPG) opened at 158.46 on Thursday. Shire PLC has a 12-month low of $139.36 and a 12-month high of $209.22. The company has a market cap of $47.20 billion, a PE ratio of 70.90 and a beta of 1.61. The company has a 50 day moving average of $153.42 and a 200-day moving average of $168.82.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 EPS for the quarter, missing the Zacks’ consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. Equities research analysts anticipate that Shire PLC will post $14.93 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.dailypolitical.com/2017/09/15/shire-plc-shpg-rating-reiterated-by-cantor-fitzgerald.html.
Several large investors have recently modified their holdings of the business. Maverick Capital Ltd. grew its stake in shares of Shire PLC by 19.9% in the 2nd quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock worth $320,969,000 after buying an additional 322,610 shares in the last quarter. Glenview Capital Management LLC grew its stake in shares of Shire PLC by 69.7% in the 2nd quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock worth $284,756,000 after buying an additional 707,500 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Shire PLC by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after buying an additional 13,665 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Shire PLC by 14.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,510,227 shares of the biopharmaceutical company’s stock worth $249,577,000 after buying an additional 194,059 shares in the last quarter. Finally, BlackRock Inc. grew its stake in shares of Shire PLC by 4,217.7% in the 1st quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after buying an additional 1,400,275 shares in the last quarter. 19.13% of the stock is owned by institutional investors and hedge funds.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.